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ABSTRACT                                                                             
G protein coupled receptors (GPCRs) mediate a multitude of responses serving 
hormonal, neurotransmitter, and sensory functions. These receptors are important drug 
targets; in fact, about 27 % of prescribed drugs are GPCR ligands. The dopamine D2 
receptor is prominently expressed within the CNS as two distinct isoforms; D2L (long 
isoform) and D2S (short isoform). The former is mainly expressed postsynaptically, 
whereas the latter functions primarily as an inhibitory auto- and heteroreceptor. The D2 
receptor is of considerable pharmacological interest, as it constitutes the main target for 
most antiparkinsonian and antipsychotic drugs in clinical use.  While many ion 
channels have long been known to be voltage sensitive, this property has not been 
attributed to GPCRs until quite recently. As a notable example, the muscarinic M2 
receptor was shown to display depolarization-induced decreases in agonist binding and 
functional potency. M2 receptor voltage sensitivity has been implicated in the 
autoreceptor function of this GPCR, by permitting rapid control of neurotransmitter 
release kinetics by membrane voltage.     
 
The present work investigated the voltage sensitivities of the three D2-like dopamine 
receptors; D2, D3, and D4. The bulk of the experiments were carried out in Xenopus 
oocytes heterologously expressing D2-like receptors with G protein-coupled inwardly 
rectifying potassium channel (GIRK) subunits. GIRK channels are activated by Gβγ 
subunits from inhibitory G proteins and were used as readout of receptor activation. It 
was found that dopamine potency was reduced by depolarization to a similar extent at 
both isoforms of the D2 receptor. However, at the dopamine D3 receptor dopamine 
potency was not significantly affected, while a weak, albeit significant potency 
decrease was observed at the dopamine D4 receptor. Moreover, in mammalian cells 
expressing fluorescent G protein subunits, changes in inter-subunit Förster Resonance 
Energy Transfer (FRET) were used as readout of D2S receptor activation. Determination 
of dopamine concentration-response relationships in single cells under simultaneous 
patch clamp revealed similar depolarization-induced potency shifts as when studying 
GIRK channel activation in oocytes. Furthermore, radioligand binding experiments 
carried out on oocytes in hyperpolarizing vs. depolarizing buffer established that 
dopamine binding is reduced by depolarization. Interestingly, the effect of voltage was 
different for different agonists at the D2S receptor, including efficacious, high-affinity 
antiparkinsonian agonists. This agonist-specificity did not reflect selective signalling 
via distinct G protein subtypes. However, contacts between agonist hydroxyl groups 
and receptor serine residues, as well as between the agonist amine group and a 
conserved aspartate residue, were found to be important for the voltage induced 
potency shift of phenethylamine agonists, such as dopamine.  
 
In conclusion, the findings presented in this thesis suggest that the dopamine D2-like 
receptors are differentially affected by voltage. At the D2S receptor, specific agonist-
receptor interactions determine the effect of the receptor’s voltage sensitivity on agonist 
potency and efficacy. This information demonstrates the relevance of GPCR voltage 
sensitivity to dopaminergic signalling, reveals new details about the mechanism of 
voltage sensitive agonism, and points to the possibility of using differentially voltage-
modulated agonists to investigate the relevance of this phenomenon in native tissue. 
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1 INTRODUCTION 
 
1.1 G PROTEIN-COUPLED RECEPTORS AND G PROTEINS 
G protein-coupled receptors (GPCRs) are a heterogeneous superfamily of 
transmembrane proteins, which share a common structural motif of seven 
transmembrane helices, and the capacity to activate heterotrimeric G proteins 
(Lagerström and Schiöth, 2008). However, the “GPCR” term has been suggested to be 
outdated, as these proteins have been shown also to signal via several other molecules 
independently of G protein activation; examples of this include activation of arrestins 
and receptor tyrosine kinases (Shukla et al., 2011). Instead, “7-transmembrane (7-TM) 
receptors” has been suggested as a more appropriate name; nevertheless, the GPCR 
acronym remains the most widely accepted, and will be used in the following treatise, 
which will focus on G protein-dependent aspects of downstream signaling. GPCRs are 
important therapeutic targets; over 25 % of prescribed drugs, by number of drug 
compounds, are GPCR ligands (Overington et al., 2006).  
 
G proteins belong to the GTPase superfamily; proteins which bind GTP that is 
subsequently hydrolyzed to GDP and inorganic phosphate. These proteins are 
heterotrimers consisting of a large Gα subunit, which contains the GTPase domain, and 
the smaller Gβ and Gγ subunits (see Oldham and Hamm, 2006). When GDP-bound or 
empty, the G protein is considered to be in its inactive, non-signaling state. Upon GTP 
binding, this complex undergoes conformational rearrangement, which confers the 
ability to initiate downstream signaling, such as activation or inhibition of adenylate 
cyclase (typically mediated via the Gα subunit) or ion channels (often via the Gβγ 
subunits; see below). When purified G proteins are investigated in solution, the GTP-
induced conformational change in the G protein trimer leads to its dissociation into two 
separate Gα and Gβγ entities. To what extent such dissociation also occurs in living cells 
is currently a matter of debate; this might be true only for some G protein subtypes 
(Lambert, 2008). In either case, both Gα and Gβγ presumably remain associated with the 
plasma membrane throughout the G protein cycle, since Gα and Gγ are covalently 
attached to lipids, which anchor them to the membrane’s inner leaflet. The signal is 
terminated by hydrolysis of the bound GTP, upon which the G protein trimer returns to 
its original, inactive conformation. To initiate a new cycle of activation, the GDP, 
which remains bound to the G protein in its inactive state, must be exchanged for a 
GTP molecule (Oldham and Hamm, 2006).       
 
Agonist binding to a GPCR triggers a series of conformational changes which are 
transmitted via the transmembrane helices to the cytoplasmic face of the receptor 
protein. In particular, the second and third intracellular loops, as well as the C-terminus, 
have been strongly implicated in the interaction of GPCRs with G proteins. The 
conformational rearrangement of these receptor domains enables activation of GDP-
bound G proteins. The active conformation of the GPCR stabilizes the empty state of 
the Gα subunit; thus, GPCR activation favors release of GDP. Subsequently, GTP, 
which in living cells is present at several-fold higher concentrations compared to GDP, 
can enter the nucleotide binding pocket of the Gα subunit and activate the G protein, 
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simultaneously destabilizing the agonist-receptor-G protein complex. (Oldham and 
Hamm, 2006).      
 
1.1.1 Dopamine receptors 
Dopamine receptors belong to the “Class 1” (also known as “Rhodopsin family” or 
“amine-like”) group of GPCRs; thus, they share significant sequence similarities with, 
for example, serotonin, histamine, muscarinic, and adrenergic GPCRs (Lagerström and 
Schiöth, 2008; Foord et al., 2005). Dopamine receptor function has been heavily 
implicated in physiological functions such as learning and memory, reward processes, 
attention and behavioral set-shifting, and the selection and execution of motor programs 
(Schultz, 2007). Aberrant dopaminergic signaling is also regarded as central to several 
common disease states (see below). There are five subtypes of dopamine receptors; D1- 
D5, which are typically subdivided into D1-like (D1 and D5) and D2-like (D2-D4) based 
on their preferential coupling to G proteins which stimulate (Gs) or inhibit (Gi/o) 
adenylate cyclase, respectively (Stoof and Kebabian, 1981). Of relevance for the 
present work, Gi/o proteins can be inactivated by pertussis toxin (PTX); a bacterial 
peptide toxin which covalently ADP-ribosylates Gi/o proteins. ADP-ribosylation 
mimics the effect of GDP occupancy on the Gi/o proteins, thus rendering them 
permanently inactive and unable to interact with their cognate receptors. As will be 
discussed below, the specificity of PTX for Gi/o proteins can be used experimentally to 
manipulate GPCR signalling pathways.  
 
1.1.1.1 D2-like subtypes 
Besides adenylate cyclase inhibition, other effector actions of D2-like dopamine 
receptors include inhibition of calcium channels, increase of dopamine re-uptake via 
the dopamine transporter (DAT), and opening of G protein-coupled inward rectifier 
potassium channels (GIRK; De Mei et al., 2009; Missale et al., 1998). GIRK channel 
activating forms the basis for the main assay used in the papers in this thesis (see 
below).  
The dopamine D2 receptor is the main target for several drugs which find clinical use in 
some common neurological, neuroendocrinological, and psychiatric disorders, notably 
including Parkinson’s disease, hyperprolactinemia, restless legs syndrome, psychosis, 
and Tourette’s syndrome; D2 agonists are used in the first three of these disorders, 
whereas antagonists or weak partial agonists are employed in treatment of the last two 
(Kvernmo et al., 2008; Prabhakar and Davis, 2008; Seeman 2010). The dopamine D2 
receptor is expressed as two distinct splice variants; D2L and D2S (long and short, 
respectively), differing by a stretch of 29 residues in the third intracellular loop (Usiello 
et al., 2000). Prominent D2 receptor expression is found within the striatum, with lower 
density expression in thalamus and prefrontal cortex. D2S functions predominantly as an 
inhibitory auto- and heteroreceptor at dopamine, glutamate, and GABA terminals in the 
CNS, whereas D2L is considered to mediate the majority of postsynaptic responses to 
dopamine, notably on the dendrites of medium spiny neurons, which constitute the 
primary neurons in the striatum (Usiello et al., 2000). 
 
The D3 receptor is also expressed in the striatum, although it displays a more restricted 
localization pattern than D2L and D2S, with predominant postsynaptic expression in the 
nucleus accumbens and the islands of Calleja (Suzuki et al., 1998). Increased dopamine 
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release in the nucleus accumbens is widely believed to serve as a reward signal, and 
consistent with this notion, recent work implicates the D3 receptor in addictive 
processes (Heidbreder and Newman, 2010). D3 is also expressed in dopaminergic 
neurons and has been suggested to act as an autoreceptor, similar to D2S, but this 
remains a controversial issue (Koeltzow et al., 1998). Whereas D2L and D2S can activate 
G protein of both the Gαi and Gαo subtypes, D3 couples exclusively to Gαo (Lane et al., 
2008).  
 
The D4 receptor, in contrast, is predominantly expressed on pyramidal cells of the 
prefrontal cortex and in the amygdala, but also shows some expression in the basal 
ganglia, both presynaptically on several types of nerve terminals, and postsynaptically 
on medium spiny neurons (Svingos et al., 2000; Rivera et al., 2002). The third 
intracellular loop of human D4 contains a variable number of tandem repeats (VNTRs) 
of 16 amino acids, of which there exist three major polymorphisms; D4.2, D4.4 and D4.7. 
Interestingly, the D4.7 polymorphism has been associated with attention-
deficit/hyperactivity disorder (ADHD) in several genetic linkage studies (Rondou et al., 
2010).  
 
1.1.2 Ligand binding at GPCRs  
Most GPCRs display states of high and low affinity binding to their agonists; the high-
affinity state generally being regarded as the signalling, G protein-coupled form of the 
receptor. Specifically, the empty (nucleotide-free) G protein is believed to stabilize the 
high-affinity state of the receptor (see above). While such high- and low-affinity states 
are readily detected in competition binding experiments performed on purified cell 
membrane fractions, there is controversy in the literature as to whether these states can 
be observed in living cells. While Seeman (2008) reported on the existence of two 
affinity states for dopamine binding in competition with a radiolabeled antagonist, 
neither Sibley et al. (1983) nor Skinbjerg et al. (2009) found evidence of biphasic 
agonist binding to D2 receptors in live cells. The structure of the antagonist used in 
these competition binding studies has been suggested to influence the ability to detect 
the two affinity states, potentially because the more lipophilic ligands, such as 
spiperone, readily cross the cell membrane and will thus also bind to internalized 
receptors, whereas relatively hydrophilic antagonists like domperidone will only access 
receptors expressed on the cell surface (Seeman et al., 2006). However, another 
controversy regarding high-affinity live cell binding concerns the stability of the ternary 
complex of receptor, agonist, and guanine nucleotide-free G protein. Since the high 
intracellular GTP concentration (150 µM; Hatakeyama et al., 1992) should promote its 
rapid breakdown, this complex presumably has a very short lifetime. Indeed, to 
visualize the two binding affinity components in membrane fractions, binding 
experiments are usually carried out in the absence of guanine nucleotides, and the 
addition of guanine nucleotides typically converts the biphasic dissociation curve into a 
monophasic one (the high affinity fraction is no longer observed). Even in membrane 
fractions, the exact mechanism giving rise to the two affinity states is controversial; 
under most conditions, the number of G proteins is assumed to exceed the number of 
GPCRs, suggesting that only one high-affinity fraction should be observed in the 
absence of guanine nucleotide (Sibley et al., 1983).  
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The existence of homo- and heteromeric receptor complexes; the assembly of GPCRs 
into dimers, oligomers, or multimers (receptor mosaics) has gained increasing attention 
in recent years (Fuxe et al., 2010). Considering dopamine D2 receptors, recent evidence 
from experiments using engineered receptor constructs suggests that the high- and low-
affinity binding states might result from negative cooperativity between two D2 
receptors forming a homodimer; agonist binding to one receptor decreases agonist 
potency at the other receptor in the dimer (Han et al., 2009). Similarly, Ma et al. (2007) 
showed that muscarinic M2 receptors oligomerize and display negative cooperativity of 
agonist binding when reconstituted together with (but not without) G protein. In 
agreement, it was suggested on the basis of modelling and crystallography data that for 
sterical reasons, only one of the protomers in a GPCR dimer could couple to G protein 
at a time (Han et al., 2009). Thus, protomer competition for G protein coupling could 
potentially explain the appearance of the two binding fractions. However, adding to the 
controversy, it has been reported that monomeric β2 adrenergic receptors reconstituted 
into lipoprotein particles also display two affinity states (Whorton et al., 2007). In this 
study, the fraction of high-affinity agonist binding increased from 0 -100 % with 
increasing concentration of the receptor’s cognate G protein; Gs, in the binding buffer, 
strongly suggesting that in this case, limited G protein binding to the GPCR indeed 
caused the partitioning of the receptor pool into high- and low-affinity fractions. 
 
The ex vivo picture is further complicated by the presence of multiple D2-like receptor 
subtypes with similar affinities for the radioligands most commonly used in binding 
studies (see below). Moreover, in the case of dopamine D2 receptors, the presence of 
heteromeric assemblies containing dopamine D1, D3, D4, and adenosine A2A, 
cannabinoid CB1, neurotensin NTS-1, serotonin 5-HT2A, have been compellingly 
demonstrated (Fuxe et al., 2010). The presence of heterodimer partners frequently 
modulates the ligand binding and cooperativity characteristics of the other interacting 
receptors. Thus, in native tissue, or in heterologous expression systems where 
endogenous heteromeric partners might exist, the binding of selective radioligands to 
D2-like receptors will not reflect binding to a single receptor species, which frequently 
complicates the interpretation of binding data.    
 
1.1.2.1 Ligand-dopamine receptor interactions 
The dopamine receptors share many features with the other amine-like GPCRs, 
especially other catecholamine receptors. Specifically, the primary amine of dopamine 
is envisaged to bind via a reinforced hydrogen-electrostatic bond to an aspartate residue 
in TM III. This aspartate residue is conserved between all amine-like receptors. The 
hydroxyl groups of dopamine are believed to form a network of hydrogen bonds with 
three serine residues in TM V (Floresca and Schetz, 2004). Serine or cysteine residues 
are located in the corresponding positions in adrenergic receptors, and have been shown 
to be involved in agonist binding also in these receptors. A π system of delocalized 
electrons (not necessarily aromatic; see Dörfler et al., 2008) is regarded as essential for 
dopaminergic activity. This ligand π system is thought to interact with a hydrophobic 
cluster of aromatic residues in TM VI, which is likely to function as an important 
switch for receptor activation (Deupi and Kobilka, 2007). Synthetic dopaminergic D2-
like ligands frequently feature hydrophobic substitutions, such as propyl chains, at the 
primary amine, which serve to increase receptor binding affinity. The existence of a 
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“propyl pocket” between TM III and TM VII, accommodating these substitutions, has 
been postulated (Malmberg et al., 1994). Most clinically used dopamine agonist and 
antagonist show less than a 100-fold selectivity for one D2-like receptor subtype of 
another, and the contribution of individual subtypes to therapeutic response remains 
controversial (Löber et al., 2011). While ligands reasonably (~150-fold) selective for 
the D3 receptor over D2 are just reaching clinical trials (e.g., for the treatment of drug 
addiction), D4-selective agonists and antagonists have been around for over a decade 
(Enguehard-Gueiffier and Gueiffier, 2006; Löber et al., 2011). Whereas the initial hope 
that D4-selective antagonists would prove efficacious antipscyhotics (due to the relative 
selectivity of the antipsychotic clozapine for D4 over D2) turned into disappointment, it 
seems at present that proerectile D4 agonists might have potential to reach the clinic 
(Löber et al., 2011).  
 
In competition binding experiments, both D2 and D4 receptors display high- and low-
affinity agonist binding sites which are converted into monophasic displacement curves 
when guanine nucleotides are included in the binding buffer. However, when the 
corresponding experiments are carried out on dopamine D3 receptors, the difference 
between high- and low-
affinity components 
often cannot be 
resolved, and when 
observed, is reported to 
be unusually low. 
Furthermore, most 
studies describe D3 
agonist binding as 
insensitive, or very 
weakly affected by, 
guanine nucleotides 
(Filteau et al., 1999). In 
agreement, agonist 
binding at this receptor 
has been reported to be 
insensitive to the 
presence or absence of 
G protein (Vanhauwe et 
al., 2000).  
 
 
 
 
 
 
 
 
 
Figure 1. 
Structural elements regarded as critical to agonist binding and efficacy at 
the dopamine D2S receptor: Asp114; conserved aspartate in TM III which 
binds the protonated amine of dopamine ligands via a reinforced 
electrostatic bond. Ser 193, 194, 197; conserved serines thought to form 
hydrogen bonding interactions with the hydrogen bond acceptors (such as 
hydroxyl groups) on the aromatic rings of agonist ligands. These 
interactions help position the ligand for interaction with the aromatic 
cluster in TM VI. Phe 361; phenylalanine in the aromatic cluster, 
important for binding to the catechol ring of dopamine agonists by a pi-
bonding interaction. Tight interaction of an agonist with the aromatic 
cluster is believed to trigger one of the “switches” for receptor activation 
(Deupi and Kobilka, 2007). Adapted from Paper III. 
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Figure 2.  
Ligands showing selectivity for D2-like receptors, and commonly used in in vitro pharmacology 
experiments. 
 
1.2 G-PROTEIN-COUPLED INWARDLY RECTIFYING POTASSIUM 
CHANNELS 
GIRK channels (also known as Kir3) are composed of four subunits, which can be 
either of four subtypes; GIRK1-4. GIRK1-3 expression is high in neuronal tissue, 
whilst GIRK4 is found mainly in the heart and in a subset of central neurons. GIRK1 
subunits occur both in the heart and the nervous system, forming heteromers with 
GIRK2, GIRK3 and GIRK4. GIRK1 cannot form functional channels on its own, but 
must assemble with the other subunits (see Mark and Herlitze, 2000, for a thorough 
review on GIRK channels). Each subunit also consists of two transmembrane domains, 
flanking the intramembrane pore region, which contains the glycine-tyrosine-glycine 
signature characteristic of potassium channels; this stretch of amino acids forms the 
narrowest part of the channel, called the selectivity filter, as it only lets potassium ions 
through.  
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The inward rectification, meaning that the GIRK channels predominantly pass current 
flowing into the cell, is caused by intracellular cations, notably Mg2+ and the 
polyamines spermine, spermidine and putrescine, which block the ion conducting pore 
at positive voltages. When the membrane potential is stepped from depolarized to 
hyperpolarized potentials, the GIRK current increases in a biphasic manner; a large, 
instantaneous current increase, which is believed to results from the unbinding of Mg2+ 
from the channel pore, is followed by a smaller and slower increase in current, which 
has been found to reflect the unbinding of polyamines (Lancaster et al., 2000).    
 
Thus, the voltage dependence of the conductance of these channels is not caused by a 
gating mechanism intrinsic to the channel protein itself, as is the case for example with 
members of the Kv family of voltage-gated potassium channels. However, the voltage 
dependence is also affected by the extracellular K+ concentration, in a way such that 
increasing the extracellular potassium concentration will shift the voltage dependence 
of the channel in the positive direction. This shift is not simply a reflection of the shift 
in potassium reversal potential, as alterations of the intracellular potassium 
concentration do not appear to affect channel voltage dependence. Rather, evidence 
suggests that extracellular K+ favours channel opening by preventing collapse of the 
pore region (Claydon et al., 2004; For detailed references on GIRK channel kinetics, 
see Hille, 2001.) 
 
GIRK channels are gated by binding to the Gβγ subunits of trimeric G proteins 
(Logothetis et al., 1987; Fig. 2). The Gβγ subunits are believed to bind to the N-and C-
termini of the subunit peptide chains, binding of separate Gβγ subunits to each of all 
four channel subunits being necessary for channel opening. Although the Gβγ subunits 
are the ones activating the channel, only G proteins in which the Gα subunit is of the 
PTX-sensitive Gi/o class couple efficiently to GIRK channels (Leaney et al., 2000). This 
is most likely because receptors, G proteins and effectors (in this case, GIRK channels) 
are arranged in close spatial proximity at the membrane, and the Gα subunit mediates at 
least part of the binding specificity in the formation of such signalling complexes 
(Lavine et al., 2002). Thus, only those GPCRs coupled to Gi/o proteins can efficiently 
exert their actions via GIRK channels.  
 
When expressed in Xenopus oocytes, GIRK channels exhibit basal activity in the 
absence of activated receptors. This activity is believed to stem from channel binding of 
Gβγ subunits, released by low-level spontaneous cycling of G proteins in the oocytes. 
This notion is supported by the observation that exogenous expression of Gα subunits 
greatly reduces the amplitude of the basal GIRK current, and also causes a 
corresponding increase in agonist-evoked current, when a Gi/o-coupled receptor is 
coexpressed. Conversely, increasing the expression of Gβγ subunits increases the basal 
current while diminishing the amplitude of the current response to receptor activation. 
(see Mark and Herlitze, 2000) 
 
Electrophysiological measurement of GIRK channel currents or fluorescence-based 
measurements of G protein conformational change in response to GPCR activation (see 
below) offer a means of studying the time course of G protein activation with high 
temporal resolution, as opposed to, e.g., biochemical assays measuring the production 
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of cAMP by adenylate cyclase or GTPγS binding (Doupnik et al., 2004; Bünemann et 
al., 2003). Measurements on the finer time scale afforded by the present technique are 
of advantage, since the rates of G protein activation and deactivation following GPCR 
activation are very likely physiologically important (Rahman et al. 2003). These rates 
can be regulated by, for example, RGS proteins (regulators of G protein signalling) 
which accelerate the rate of GTP hydrolysis by Gα subunits (i.e., the RGS proteins are 
GTPase activating proteins) and, although not studied here, form part of many GPCR-
G protein-effector signalling complexes in vivo (see Doupnik et al., 2004). 
Furthermore, the G protein/GIRK channel population kinetics can give information 
about ligand binding kinetics - e.g.; the population rate of GIRK deactivation upon 
agonist removal has been found to reflect the rate of agonist unbinding from the GPCR 
(Benians et al., 2003).       
 
 
Figure 3. 
GIRK activation by Gi/o-coupled GPCRs. 
 
1.3 GPCR VOLTAGE SENSITIVITY 
Whereas GPCRs have not traditionally been regarded as sensitive to membrane 
potential, increasing evidence to this effect has accumulated in recent years (see 
Mahaut-Smith et al., 2008; Parnas and Parnas, 2010). Decreases in agonist potency and 
binding at Gi/o-coupled M2 muscarinic receptor and glutamate mGluR3 upon membrane 
depolarization were shown by electrophysiological assays in Xenopus oocytes, using 
GIRK opening as readout of receptor activity, as well as by radiolabeled agonist 
binding experiments performed on intact oocytes (Ben-Chaim et al., 2003; Ohana et 
al., 2006). Conversely, for Gq-coupled M1 muscarinic receptor and mGluR1 
depolarization caused an increase in agonist potency and binding (Ben-Chaim et al. 
2006, Ohana et al., 2006). In other studies of lysophosphatidic acid receptors expressed 
in oocytes, as well as P2Y1 and other Gq-coupled receptors in rat megakaryocytes, 
increases in agonist potency were observed upon depolarization (Martinez-Pinna et al., 
2010; Gurung et al., 2008). 
 
As pointed out by Bolton and Zholos (2003), these observations suggest that GPCRs 
with opposing effects on membrane excitability (e.g., Gi/o-coupled receptors activating 
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GIRK channels and inhibiting P/Q- and N-type calcium channels, Gq-coupled receptors 
closing a number of different potassium channels via phosphatidylinositol 4,5-
bisphosphate [PIP2] hydrolysis) are affected by membrane potential in opposite ways, 
so as to stabilize cell excitability; possibly helping to define “up- and down-states”, as 
has been described for principal cells of the cortex and the striatum. Up- and down-
states of principal cells of the striatum and the prefrontal cortex last several hundreds of 
milliseconds up to seconds, respectively, (Murer et al., 2002; O’Donnell, 2003); 
enough time for GPCR voltage-dependence to have an impact on downstream 
effectors, such as ion channels, especially when considering that the kinetics of native 
GPCR-G protein coupling are accelerated by RGS proteins (see Doupnik et al., 2004).  
 
Ben-Chaim et al. (2006) recorded charge movement within the M2 receptor which 
correlated with the voltage-dependent shift in binding affinity, and Kupchik et al. 
(2011) as well as Navarro-Polanco et al. (2011) further demonstrated that this charge 
movement is affected by the presence of receptor ligands in a concentration-dependent, 
ligand-specific manner. These findings suggest that parts of the receptor itself move 
upon changes of the membrane potential; presumably, one or several charged, voltage-
sensing residues move in response to voltage changes, and these movements are 
relayed to the ligand binding site of the receptor.  
 
Ben-Chaim et al. (2003; 2006) and Ohana et al. (2006) suggested that depolarization 
affects the coupling of receptor to G protein, and that the depolarization-induced 
decreases in agonist binding and potency at Gi/o-coupled receptors reflects shifts in the 
fractions of receptors configured in the high- and low-affinity states. E.g., in the case of 
the M2 receptor, depolarization was envisaged to uncouple a fraction of the receptor 
pool from Gi/o protein, thereby shifting this fraction from high to low agonist affinity. In 
support of this hypothesis, Ben-Chaim et al. (2006) presented data showing that 
depolarization had no effect on the binding of radiolabeled acetylcholine to M2 
receptor-expressing oocytes treated with PTX.  
 
An increase in the fraction of high-affinity binding of D2 receptors has been 
consistently reported in animal models of psychosis (Seeman et al., 2006). The putative 
voltage-sensitivity of the dopamine D2 receptor could provide a link between the 
observed alterations in receptor affinity and functional disturbances in basal ganglia 
synaptic plasticity and neuron firing patterns. Furthermore, comparison between the 
voltage-sensitivities of different pairs of receptors and ligands might provide insight 
into the mechanistic basis of GPCR voltage sensitivity, and of receptor affinity states in 
general. Thus, we were interested in determining the potential impact of membrane 
voltage on the pharmacology of dopamine D2-like receptors.  
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2 AIMS OF THE THESIS 
 
The general aim of the present work has been to investigate the putative impact of 
transmembrane voltage on the pharmacology of dopamine D2-like receptors. The initial 
goal was:  
 
To determine whether agonist potency at the dopamine D2L receptor is affected by 
transmembrane voltage 
 
As work progressed, further specific aims were defined: 
 
To compare the voltage sensitivities of dopamine potency at the different 
dopamine D2-like receptors 
 
To compare the effects of voltage on the potencies of different agonists at the 
dopamine D2S receptor 
 
To explore the ligand-receptor interactions underlying agonist-specific effects of 
voltage on dopamine D2S receptor pharmacology 
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3 METHODOLOGICAL CONSIDERATIONS 
 
Here, some basic principles and practical considerations regarding the experimental 
methods are presented. For details on the specific experimental protocols used, please 
refer to the methodological sections of the papers. 
 
3.1 MOLECULAR BIOLOGY 
DNA encoding the relevant receptors and channel subunits was obtained in plasmids 
suitable for in vitro transcription of RNA. The plasmids were linearized 3’ to the 
coding sequence of the insert using restriction enzymes of the appropriate specificity. 
RNA was subsequently transcribed in vitro from the linearized plasmids using T7 or 
SP6 RNA polymerase kits (Ambion, Austin, TX, USA). Some of the receptor 
constructs used were cloned into the pXOOM vector. This dual-purpose vector contains 
both a cytomegalovirus (CMV) promoter that enables mammalian expression as well as 
untranslated regions from the Xenopus β-globin gene, which are located downstream 
the T7 promoter and 5’ and 3’ to the coding sequence. These untranslated regions are 
thus included in RNA transcribed in vitro from this plasmid, and often increase 
expression of the RNA in oocytes as they bind to proteins which prevent RNA 
degradation and enhance the efficiency of its translation by ribosomes (Jespersen et al., 
2002). This vector was a gift from Dr. Søren-Peter Olesen, University of Copenhagen, 
Denmark. 
 
3.2 THE XENOPUS OOCYTE EXPRESSION SYSTEM 
Xenopus oocytes are obtained from the African clawed toad, Xenopus laevis.  
The oocyte expression system has long been a popular system for electrophysiological 
testing of drug candidates in the pharmaceutical industry, as well as being used in 
several other types of electrophysiological and molecular biological investigations in 
the academic setting. Advantages of using Xenopus oocytes for heterologous 
expression of ion channels include their capacity for synthesizing large amounts of 
protein, their huge size (1mm diameter) enabling microinjection of individual oocytes 
with mRNA, assuring expression in virtually every cell, and their relatively low 
expression of endogenous ion channels. Potential drawbacks of the Xenopus system 
include the fact that it is a non-mammalian expression system; for example, protein 
glycosylation and intracellular trafficking might differ from mammalian cells. For an 
extensive review on the use of Xenopus oocytes in ion channel research, see Dascal 
(1987).  
 
3.3 ELECTROPHYSIOLOGY 
Electrophysiology is the measurement of electrical signals from a biological specimen. 
In the present context, we will consider electrophysiology experiments performed on 
single cells. Electrical contact with the cells under study is usually achieved using 
micropipettes, made from glass capillaries by simultaneous heating and pulling on the 
glass. The micropipette contains a conductive salt solution, which is in contact with an 
electrode, typically a silver-silver chloride electrode.   
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Voltage-clamp electrophysiology provides a measure of the ionic current flow across a 
biological membrane at a given membrane potential. This is accomplished by a 
negative feedback amplifier, which continuously measures the membrane potential 
(i.e., the potential inside the cell minus the potential in the extracellular solution) and 
compares it to a desired command voltage. As soon as the measured potential deviates 
ever so slightly from the command voltage, current will be injected by the feedback 
circuitry so as to bring the measured voltage back to the value of the command voltage. 
During optimal conditions, any charge transfer across the membrane (which would tend 
to alter the membrane potential if left unopposed) will be compensated for by an 
opposing charge transfer induced by the feedback amplifier. Thus, the current injected 
to maintain the membrane voltage at its desired value is a measure of the current 
flowing across the membrane at that voltage, and can thus be used to study the opening 
and closing of ion channels.  
 
3.3.1 Whole-cell voltage clamp using the patch-clamp technique 
When using the patch-clamp technique in the whole-cell configuration, which is a 
popular mode of electrophysiological recording from small mammalian cells, a glass 
microelectrode is advanced toward the cell until it is just above or slightly touches the 
membrane. At this point, negative pressure is carefully applied to the pipette (typically 
by pulling on a syringe attached to the electrode holder, the interior of which is 
continuous with the micropipette). When performed correctly, this maneuver will cause 
the cell membrane to adhere tightly to pipette, forming what is known as a “gigaohm 
seal”; referring to the high electrical resistance between the pipette and the membrane. 
Next, stronger negative pressure is applied to the pipette, causing the membrane patch 
just under pipette opening to rupture. The interior of the cell is now continuous with the 
interior of the pipette, and all currents passing through the cell membrane can (under 
ideal conditions) be measured by clamping the cell membrane voltage, as just 
described. In a typical experiment, the pipette solution will rapidly equilibrate with the 
intracellular solution, a fact which should be considered when preparing the pipette 
solution. The equilibration of pipette and intracellular solutions can be useful in case 
one wants to modify the internal milieu of the cell; e.g. by delivering pharmacological 
agents.  
   13 
 
Figure 4. 
Schematic illustration of the patch clamp technique, as explained in the main text, above. 
 
 
3.3.2 Whole-cell voltage clamp using the two-electrode technique 
The large size and efficient protein expression of the oocyte also means that the 
currents recorded from these cells will frequently be very large –usually on the order of 
µAs. Injection of such big currents through a high-resistance pipette would lead to a 
large voltage drop over the pipette, leading to a falsely low estimate of the membrane 
potential, if the current-passing electrode was to be used also as a voltage-sensing 
electrode. The two-electrode system overcomes this potential problem, by (as the name 
implies) using two separate electrodes for current injection and voltage-sensing. 
Furthermore, to lower the resistance of the pipettes, thus easing the injection of large 
currents by the amplifier, saturated salt solutions (e.g., 3 M KCl), are commonly used 
in the pipettes instead of physiological intracellular solutions. As opposed to patch-
clamp experiment, in two-electrode experiments the microelectrodes are pushed 
through the cell membrane, rather than forming a gigaohm seal before gaining access to 
the cell interior. This is possible because the vitelline layer, a thin sheet of protein 
enveloping the oocytes, and the large size of the oocyte provide mechanical stability, 
preventing the cell from collapsing when the electrodes are inserted. 
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Two-electrode experiments are easier to perform than patch-clamping, but do not allow 
for control of the internal environment of the cell, as does whole-cell patch-clamping of 
mammalian cells, in which the pipette solution equilibrates with the solutes in the cell 
cytoplasm. In fact, in two-electrode experiments, influx of pipette solution into the 
oocyte interior is to be avoided, because of the non-physiological nature of the 
saturated salt solution. In the present work, influx of pipette solution was prevented by 
filling the pipette tips with a molten agarose-KCl gel, which was allowed to solidify 
before backfilling the pipette with 3 M KCl solution, as originally described by 
Schreibmayer et al. (1994). Also, the large capacitance of the oocyte membrane means 
that it is slower to clamp compared to that of a small cell; i.e., the kinetics of fast 
currents such as those passed by voltage-gated sodium channels cannot be accurately 
resolved. However, for the present purposes this is not a problem, given the relatively 
slow kinetics of GPCR-induced GIRK channel activation. Finally, the vitelline layer 
has been shown to impede the diffusion of some pharmaceutical compounds, slowing 
the rate of onset of their action and skewing their concentrations of action toward 
higher values (Madeja et al., 1997). The large size of oocytes also increases the time 
required for a drug to reach all areas of the cell membrane, which might give a “false” 
slowing of response kinetics of agonist-activated channels under certain circumstances 
(Doupnik et al., 2004). 
 
Figure 5. 
Principles of the Xenopus oocyte expression system and two-electrode voltage clamp, as explained in the 
main text, above. 
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3.4 FRET ASSAY PRINCIPLES 
Förster Resonance Energy Transfer (FRET), also known as Fluorescence Resonance 
Energy Transfer, is the radiationless (i.e., without photon emission) transfer of energy 
from the excited electronic system of one dye molecule (for present purposes; a 
fluorophore) to the electronic system of another dye molecule in close proximity (see 
Lohse et al., 2008). The efficiency of this energy transfer is dependent both on the 
extent of overlap between the emission spectrum of the first dye and the excitation 
spectrum of the second, as well as on the distance between the two molecules involved; 
The efficiency of energy transfer decreases with the sixth power of the distance 
between the molecules, enabling the use of FRET-based assays to report on inter- and 
intramolecular motion on the scale of a few nm. Two genetically encoded fluorophores 
forming a suitable FRET pair are Cyan fluorescent protein (CFP) and Yellow 
fluorescent protein (YFP).  
In the present experiments, an immortalized mammalian cell line (HEK 293T) was 
transiently transfected with the constructs of interest (the human dopamine D2 receptor, 
Gαi1-YFP, CFP-Gβ1, Gγ2) and grown on coverslips for 3-5 days prior to experiments. 
During an experiment, a healthy-looking cell is selected on the basis of its membrane-
associated expression of the fluorescent constructs (as judged using a fluorescence 
microscope; Zeiss Axio Observer). The CFP tag is excited at 436 nm, upon which it 
emits light with an intensity maximum at 480 nm. The excitation light is generated 
using a monochromator (Polychrome V, Till Photonics). In the monochromator, white 
light from a Xenon lamp is split into its component wavelengths using a diffraction 
grating. As just described, when the two fluorophores are sufficiently close together, 
part of the energy absorbed by CFP is donated to YFP (whose excitation maximum is 
about 505 nm), which then emits at 535 nm. Since the amount of energy transferred 
between two fluorophores is dependent on their distance, conformational change in the 
G protein trimer upon its activation by the dopamine D2S receptor can be studied by 
recording the emission ratios of CFP and YFP (i.e., the ratios of intensities at 480 and 
535 nm; Bünemann et al., 2003). In the experimental setup used in the present 
experiments, the emitted light is separated into CFP and YFP channels using a dichroic 
mirror, and subsequently measured using photodiodes connected to an amplifier (Till 
Photonics; see Bünemann et al., 2003). By selecting which part of the field of view is 
transmitted to the photodiodes, FRET data can be collected from single cells expressing 
the fluorescent constructs. The equipment used in the present experiments also 
minimizes the extent of photobleaching; during prolonged excitation, fluorophores tend 
to undergo chemical decomposition due to oxidative processes during repeated 
excitation and emission. By using a galvanometer mirror, the monochromator is able to 
turn the light delivered to the specimen on and off at high frequencies, thus providing 
intermittent excitation of the fluorophores. This reduces the photobleaching of the 
fluorophores over time, as compared to continuous excitation. 
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Figure 6.   
Schematic showing the principles of the FRET assay of G protein activation, as explained in the main 
text, above. 
 
3.5 RADIOLIGAND BINDING EXPERIMENTS 
Radioligand binding assays are based on the principle of using radioactively labelled 
molecules with affinity for a receptor of interest to investigate the distribution, density, 
or ligand binding properties of that receptor. In the present experiments, the binding of 
[3H]-labelled dopamine to Xenopus oocytes coexpressing dopamine D2S receptors with 
GIRK channels was investigated under hyperpolarizing and depolarizing conditions. 
The oocytes were incubated for 30 s with 40 nM or 80 nM of [3H]dopamine, in a 
physiological buffer solution or in a buffer solution in which Na+ had been replaced 
with K+. In GIRK-expressing oocytes, the resting membrane potential is determined 
largely by the reversal potential for K+, and thus elevating extracellular K+ to near the 
intracellular concentration brings the membrane potential up from about -80 mV in 
physiological solution to about 0 mV (Ben-Chaim et al., 2003). Following incubation 
with radioligand, the oocytes were washed for 1 s, again in physiological or high- K+ 
buffer, and the bound radioactivity was subsequently measured using a scintillation 
counter. Non-specific binding was determined by measuring [3H]dopamine binding to 
oocytes expressing GIRK channels without D2S receptors, and specific binding was 
determined by subtracting the average non-specific binding from the total binding in 
each oocyte coexpressing D2S receptors with GIRK channels.  
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4 RESULTS AND DISCUSSION 
 
 
Paper I: 
The putative voltage sensitivity of the dopamine D2L receptor was examined by 
determining the potencies of dopamine and the widely used D2-like agonist quinpirole 
in the GIRK activation assay described under “Methodological considerations”. It was 
found that the potencies of both dopamine and quinpirole to activate GIRK channels is 
reduced by about tenfold when the membrane is held at +40 mV, as compared to -80 
mV. It was also found that this reduction in potency was not an artifactual result of 
altered current-voltage relationships of the GIRK channel. Since G protein activation 
and Gβγ-induced GIRK channel activation have been shown to be voltage insensitive 
processes (Ben-Chaim et al., 2003), it was concluded that that the voltage-sensing 
mechanism behind the observed potency shift is likely to reside within the dopamine 
D2L receptor.  
 
 
Paper II: 
The potencies of dopamine to activate GIRK channels via dopamine D2S, D3, and D4.4 
receptors at 0 mV and at -80 mV were studied. As opposed to the previous study, 0 mV 
was used as the depolarized potential in most experiments, since it was easier to obtain 
stable recordings at this potential than at +40 mV. Furthermore, using 0 mV rather than 
+40 mV prevents the opening of an endogenous, slowly activating Na+ conductance 
(Baud and Kado, 1984), which in some oocytes is large enough to considerably 
contaminate GIRK current measurements. It was found that the D2S receptor was 
similarly voltage sensitive as the D2L receptor isoform (here, depolarization to +40 mV 
was used as well, to allow comparison). The potency shift between -80 mV and 0 mV 
was about 4.5-fold for the D2S receptor, whereas the dopamine D3 did not show any 
significant potency shift between these two potentials. Considering the proposed link 
between G protein coupling and voltage-sensitive potency (Ben-Chaim et al., 2003) 
and the previous observation of G protein-independent high-affinity agonist binding at 
the dopamine D3 receptor (Vanhauwe et al., 2000), we also investigated a chimeric 
D3/D2 receptor, which had previously been shown to display G protein-sensitive 
dopamine binding (Filteau et al., 1999). However, this chimera did not show any 
significant depolarization-induced shift. Finally, the dopamine D4.4 receptor was shown 
to display a significant loss of dopamine potency with depolarization, which was about 
2-fold; smaller than that of the D2S receptor. This study thus demonstrated differences 
in voltage-sensitivity between D2-like receptors, but was unable to demonstrate a clear 
link between G protein-sensitivity of agonist binding and sensitivity to voltage. 
 
 
 
 
 
 
 
 18 
 
Paper III: 
The voltage sensitivities of a range of structurally related agonists at the dopamine D2S 
receptor were investigated. It was found that neither the potencies nor the efficacies of 
phenethylamine agonists lacking the two hydroxyls of dopamine were significantly 
altered by depolarization from -80 mV to 0 mV. However, agonists of the dipropyl-
aminotetralin (DPAT) series were similarly voltage sensitive, regardless of 
hydroxylation. Differential engagement of G protein subtypes did not underlie the 
agonist-specific differences in voltage sensitivity, since both voltage-sensitive and 
insensitive behaviour (by dopamine and p-tyramine, respectively) was observed when 
PTX was used to constrain D2 receptor signalling so as to occur exclusively via 
exogenous PTX-insensitive Gαo1 proteins. Thus, it appears that specific agonist-receptor 
interactions determine the effect of voltage on agonist potency, rather than a general 
decoupling of G protein, as suggested by Ben-Chaim et al. (2003; 2006), and later by 
Kupchik et al., (2011). 
  
 
Paper IV: 
The agonist-specific effects described in Paper III were examined in more detail by 
using site-directed mutagenesis of the D2S receptor ligand binding pocket, as well as a 
wider selection of agonists as compared to Paper III.   
 
It was also established that the depolarization-induced decrease of dopamine potency is 
reflected in decreased binding of radiolabeled dopamine, thus supporting the notion that 
the reduced functional potency of dopamine at depolarized voltages reflects lower 
binding affinity. Furthermore, voltage sensitive dopamine potency was observed in a 
mammalian cell line using a FRET-based G protein activation assay, demonstrating 
that D2S receptor voltage sensitivity is not dependent on GIRK coexpression, nor is it 
only observed when the receptor is expressed in Xenopus oocytes. 
 
Site-directed mutagenesis data supported the hypothesis from Paper III that interactions 
between agonist hydroxyls and the conserved TM V serine residues of the D2S receptor 
are important for voltage sensitivity of phenethylamine agonists. Specifically, mutation 
of serine 193 to alanine (S193A) drastically decreased the voltage sensitivity of 
dopamine potency; only a 1.5-fold shift was observed, whereas S194A did not have a 
pronounced effect in this regard. Voltage sensitivity of dopamine at the S197A mutant 
could not be assessed, since dopamine failed to evoke quantifiable GIRK currents via 
this mutant. The unhydroxylated agonist DPAT showed depolarization-induced shifts 
of between 2.3–fold to 3.5–fold at all three mutant receptors (at the wt receptor, DPAT 
showed a 3.2-fold shift), suggesting that serine mutation did not grossly perturb 
receptor voltage-sensitivity.  
 
The agonist structure-function analysis was also extended to include the amine head 
group frequently present in amine receptor ligands. Removing the ethylamine side 
chain of dopamine leaves catechol, a compound which has been shown to act as a weak 
partial agonist at the β2 adrenergic receptor (Swaminath et al., 2005). Catechol was 
shown to be a partial agonist also at the D2S receptor, although it was impossible to 
obtain complete concentration-response relationships for this molecule because of its 
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GIRK channel-blocking effects at concentrations above 1 mM. Interestingly, the 
fractional responses for catechol (relative to a maximally effective concentration of 
dopamine) was higher at 0 mV than at -80 mV, suggesting that the potency or efficacy 
of catechol was increased by depolarization. Reciprocally, mutating the conserved 
aspartate residue, D114, to alanine (D114A), resulted in a receptor at which dopamine 
potency was increased at 0 mV, relative to -80 mV.   
 
Finally, a number of therapeutic agonists were investigated; three ergoline compounds 
(bromocriptine, lisuride, and pergolide), two aporphines (apomorphine and N-propyl-
norapomorphine) and four unrelated compounds (piribedil, pramipexole, ropinirole, 
and rotigotine). Whereas the aporphines showed no significant voltage-induced shifts in 
potency nor efficacy, the ergolines all showed a significant decrease in efficacy, and 
about 2-fold shifts in potency (significant for pergolide and bromocriptine) at 0 mV vs. 
-80 mV. Decreased efficacy was observed also for piribedil and rotigotine, and 
decreased potency for piribedil, pramipexol, and ropinirole.  
 
This study corroborated our earlier findings regarding agonist-specific voltage 
sensitivity, and strengthened our hypothesis that agonist-receptor interactions determine 
the effect of the D2S receptor’s voltage sensitivity on agonist potency and efficacy. 
Furthermore, the finding that highly affine and efficacious dopamine agonists differ 
widely in terms of how they are affected by voltage points to the possibility of using 
differentially voltage-modulated agonists to investigate the relevance of dopamine D2 
receptor voltage sensitivity in native tissue. 
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5 CONCLUSIONS 
The present work provided the first reports on voltage sensitivity of the dopamine D2-
like receptors, showing that both D2 isoforms, D4, but not D3, are regulated by 
membrane voltage (Paper I and II). Furthermore, for the first time, it was demonstrated 
that different agonists acting at the same receptor can be affected by the receptor’s 
voltage sensitivity in qualitatively different ways (Paper III and IV). For example, 
while potency and efficacy of the antiparkinsonian agonist piribedil are diminished by 
depolarization, neither parameter is affected in the case of apomorphine (another 
antiparkinsonian), and the fractional responses to the “agonist fragment”, catechol, 
were greater at depolarized potentials. Moreover, it was found that the diverse effects of 
voltage on agonist potency correlated with certain agonist-receptor interactions (Paper 
IV). These results contribute evidence that the effects of voltage on agonist potency are 
indeed brought about by voltage-induced changes in agonist-receptor interactions. 
 
Together with recent findings by Kupchik et al. (2011) and Navarro-Polanco et al. 
(2011) that agonists affect GPCR gating charge movements, the present evidence 
supports the notion that a (yet-to-be-identified) voltage sensor within a voltage sensitive 
GPCR moves within the transmembrane voltage field, which in turn causes allosteric 
changes in the agonist binding pocket, as suggested by Ben-Chaim et al. (2003; 2006). 
For the Gi/o-coupled receptors investigated so far, these changes seem to decrease the 
binding affinity for the native GPCR agonist (with the exception of the D3 receptor, at 
which dopamine potency was unchanged upon depolarization). Since many Gi/o-
coupled receptors are autoreceptors, these findings are in line with the suggested role 
for GPCR voltage sensitivity in the regulation of neurotransmitter release kinetics (see 
Parnas and Parnas, 2010). Whilst being in overall agreement with the pioneering work 
of the Parnas group, the present data argue against the idea that voltage changes the 
overall degree of G protein coupling of a voltage sensitive GPCR, since such a 
mechanism would be expected to produce similar effects on all agonists at the receptor 
in question. Rather, it appears that the equilibrium between certain agonist-bound 
receptor conformations is shifted by membrane potential changes, such that, at a given 
GPCR, voltage has distinct effects on the affinities and efficacies of different ligands.   
 
The results presented in paper IV further suggest that the degree of voltage sensitivity 
of a receptor-ligand interaction is not simply related to its affinity; both some of the 
largest and some of the smallest (non-significant) potency shifts are observed with 
agonists which show EC50s in the nanomolar range, and which are reported to show 
correspondingly high affinities in radioligand binding studies (see Seeman, 2007). The 
present findings that dopamine D2 and D4 receptors are regulated by membrane voltage 
might have important implications for the function of these receptors in regulating 
transmitter release and in dopamine-mediated synaptic plasticity.   
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6 FUTURE DIRECTIONS 
The present results demonstrate the effect of voltage on dopamine D2 receptor 
pharmacology at the ligand binding, G protein, and effector levels. However, all of 
these studies were carried out in heterologous expression systems, which might not 
faithfully reproduce all aspects of the in vivo situation, e.g., in terms of receptor-
interacting proteins. Thus, future studies should examine the relevance of dopamine D2-
like receptor voltage sensitivity under more physiological conditions; e.g., in acute ex 
vivo preparations.  
 
Another crucial aspect deserving future attention concerns the temporal aspects of 
depolarization. The voltage-sensitive GPCR regulation of transmitter release described 
above occurs at a sub-millisecond time scale, and has been suggested to proceed via 
direct interaction between the receptor and vesicle-associated proteins (Kupchik et al., 
2008). Thus, this process is fast enough to be affected by a single action potential. 
However, in order for voltage to impact G protein activation, altered requires several 
hundreds of milliseconds. However, since depolarization has been proposed to impact 
ligand binding affinity on a sub-millisecond time scale (Kupchik et al., 2011), and the 
process from agonist binding to GPCR and G protein activation has been shown to be 
slower by about two and three orders of magnitude, respectively (Vilardaga, 2011), it is 
conceivable that also intermittent depolarizations, applied over a few seconds (as 
during a train of action potentials) might significantly impact the level of G protein 
activity induced by voltage sensitive GPCRs.  
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